Preclinical research involving individuals with metabolic dysfunction-associated steatohepatitis (MASH) indicated that GLP-1 RAs may decrease hepatic inflammation through processes that are partially unrelated to weight loss. The gene discussed is GLP1R; the disease is metabolic dysfunction-associated steatohepatitis.